Javascript must be enabled to continue!
Pharmacokinetics of antiviral polyoxometalates in rats
View through CrossRef
Polyoxometalates are soluble mineral compounds formed principally of oxide anions and early transition metal cations. The polyoxometalates K12H2[P2W12O48].24H2O (JM 1591), K10[P2W18Zn4(H2O)2O68].20H2O (JM 1596), and [(CH3)3NH]8[Si2W18Nb6O77] (JM 2820) demonstrate potent antiviral activity against human immunodeficiency virus types 1 and 2, herpes simplex virus, and cytomegalovirus in vitro. The preclinical pharmacokinetics of these three compounds were characterized after single-dose intravenous administration of 50 mg/kg to rats. Plasma, urine, and feces were collected for 168 h, and polyoxometalate concentrations were determined by atomic emission. Serum protein binding was measured by equilibrium dialysis. All three compounds were highly bound to serum proteins in a concentration-dependent manner. Total and unbound concentrations of the three compounds in plasma declined in a triexponential manner with terminal half-lives of 246.0 +/- 127.0, 438.4 +/- 129.4, and 32.2 +/- 5.37 h (mean +/- standard deviation) for JM 1591, JM 1596, and JM 2820, respectively. Systemic clearances based on total concentrations in plasma were low, averaging 0.016 +/- 0.002, 0.015 +/- 0.002, and 0.018 +/- 0.003 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. The clearances of unbound compounds from plasma averaged 0.966 +/- 0.136, 0.050 +/- 0.005, and 0.901 +/- 0.165 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. For JM 1596, the clearance of unbound compound from the kidneys was lower than the glomerular filtration rate (0.086 liter/h/kg), suggesting this polyoxometalate underwent renal tubular reabsorption. However, JM 1591 and JM 2820 appeared to undergo tubular secretion. The fraction of the dose recovered in urine was 11.5, 46.8, and 10.6% for JM 1591, JM 1596, and JM 2820, respectively. Approximately 5% of the dose of each polyoxometalate was recovered in feces. The steady-state volume of distribution based on total concentrations averaged 1.44 liters/kg for JM 1591, 2.39 liters/kg for JM 1596, and 0.59 liter/kg for JM 2820, indicating moderate to wide distribution throughout the body. All three compounds were detected in various tissues 1 week after single-dose administrations, with the highest levels found in the kidneys and liver. The results of this study indicate that the disposition of polyoxometalates is highly dependent on their molecular structure.
American Society for Microbiology
Title: Pharmacokinetics of antiviral polyoxometalates in rats
Description:
Polyoxometalates are soluble mineral compounds formed principally of oxide anions and early transition metal cations.
The polyoxometalates K12H2[P2W12O48].
24H2O (JM 1591), K10[P2W18Zn4(H2O)2O68].
20H2O (JM 1596), and [(CH3)3NH]8[Si2W18Nb6O77] (JM 2820) demonstrate potent antiviral activity against human immunodeficiency virus types 1 and 2, herpes simplex virus, and cytomegalovirus in vitro.
The preclinical pharmacokinetics of these three compounds were characterized after single-dose intravenous administration of 50 mg/kg to rats.
Plasma, urine, and feces were collected for 168 h, and polyoxometalate concentrations were determined by atomic emission.
Serum protein binding was measured by equilibrium dialysis.
All three compounds were highly bound to serum proteins in a concentration-dependent manner.
Total and unbound concentrations of the three compounds in plasma declined in a triexponential manner with terminal half-lives of 246.
0 +/- 127.
0, 438.
4 +/- 129.
4, and 32.
2 +/- 5.
37 h (mean +/- standard deviation) for JM 1591, JM 1596, and JM 2820, respectively.
Systemic clearances based on total concentrations in plasma were low, averaging 0.
016 +/- 0.
002, 0.
015 +/- 0.
002, and 0.
018 +/- 0.
003 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively.
The clearances of unbound compounds from plasma averaged 0.
966 +/- 0.
136, 0.
050 +/- 0.
005, and 0.
901 +/- 0.
165 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively.
For JM 1596, the clearance of unbound compound from the kidneys was lower than the glomerular filtration rate (0.
086 liter/h/kg), suggesting this polyoxometalate underwent renal tubular reabsorption.
However, JM 1591 and JM 2820 appeared to undergo tubular secretion.
The fraction of the dose recovered in urine was 11.
5, 46.
8, and 10.
6% for JM 1591, JM 1596, and JM 2820, respectively.
Approximately 5% of the dose of each polyoxometalate was recovered in feces.
The steady-state volume of distribution based on total concentrations averaged 1.
44 liters/kg for JM 1591, 2.
39 liters/kg for JM 1596, and 0.
59 liter/kg for JM 2820, indicating moderate to wide distribution throughout the body.
All three compounds were detected in various tissues 1 week after single-dose administrations, with the highest levels found in the kidneys and liver.
The results of this study indicate that the disposition of polyoxometalates is highly dependent on their molecular structure.
Related Results
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
Network controllability analysis reveals the antiviral potential of Etravirine against Hepatitis E Virus infection
Network controllability analysis reveals the antiviral potential of Etravirine against Hepatitis E Virus infection
Abstract
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis in lower- and middle-income countries. HEV infection may lead to acute...
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Abstract: This study aimed to establish a reasonable population pharmacokinetic model for rifampicin taken orally by patients with pulmonary tuberculosis, estimate pharmacokinetic ...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
10th Annual Meeting, 25‐26 November 1976, Adelaide 1. Histamine metabolism in aortae of two histamine sensitive species. A. Foldes, M. J. Stacey and I. S. de la Lande 2. Localizat...
Acute kidney injury during pregnancy leads to increased sFlt-1 and sEng and decreased renal T regulatory cells in pregnant rats with HELLP syndrome
Acute kidney injury during pregnancy leads to increased sFlt-1 and sEng and decreased renal T regulatory cells in pregnant rats with HELLP syndrome
Abstract
Background
The incidence of acute kidney injury (AKI) during pregnancy precedes a high maternal mortality rate o...
Abstract 1653: FcRn humanized rats for pharmacokinetics assessment of antibody drugs
Abstract 1653: FcRn humanized rats for pharmacokinetics assessment of antibody drugs
Abstract
Introduction:
Biocytogen's B-hFcRn rat model serves as a practical tool for assessing the pharmacokinetics/pharm...
Electrochemistry of Polyoxometalates: From Fundamental Aspects to Applications
Electrochemistry of Polyoxometalates: From Fundamental Aspects to Applications
AbstractElectrochemistry of polyoxometalates is very rich, as many of them can accommodate many electrons without their structure changing. Recently, extensive attention has been p...
Long‐term consequences of acute kidney injury during pregnancy
Long‐term consequences of acute kidney injury during pregnancy
OBJECTIVE
Women with severe preeclampsia and HELLP syndrome (sPE/HELLP) are more likely to develop acute kidney injury (AKI) compared to women without sPE/HELLP...

